As a science-based organisation, our research and development (R&D) activities are central to our commitment to restoring brain health.
Lundbeck’s R & D is aimed at enabling the discovery and development of new pharmaceuticals targeting the underlying mechanisms of brain diseases. This requires comprehensive research in the biology and the mechanisms of the diseases, as well as improved understanding of research targets and clinical outcomes. Over the years, we have built a broad and robust platform within psychiatry and neuro-degeneration, which allows us to use small molecules, antibodies and vaccines in thedevelopment of new medicines that can treat symptoms more effectively and potentially also alter the course of the diseases.
Research at Lundbeck is based on the efforts of our multidisciplinary project teams, our in-house expertise in the brain disease area and new technologies. We work in state-of-the-art laboratories. In each project team, we integrate our advanced knowledge in R&D disciplines with expertise in clinical practices and therapeutic needs.
We work together as individuals towards common goals. We seek to constantly develop and improve our scientific and personal skills and qualifications. This allows us to promote career opportunities for the individual, as well as maintain and develop our competencies as an organisation. Publication of our scientificresults is a natural part of our participation as active members in the international scientific community.
Lundbeck’s long experience and continuous work within diseases of the brain has provided us with a strong global network in preclinical and clinical neuroscience research. It is essential for us to maintain our strong internal R & D capabilities and to build external alliances to supplement our capabilities, taking advantage of the increased opportunities provided by innovative technologies.
In the United States, Lundbeck also joined the personal genetics company 23andMe, Inc. and the think tank The Milken Institute in a large new study to increase the understanding of the underlying causes of Major Depressive Disorder (MDD) and bipolar depression. This study further explores how these diseases and brain functions such as attention and decision-making are related to genetics.
Another international example is our participation in the RADARCNS collaboration with the scope to develop new ways of monitoring conditions such as MDD, epilepsy and multiple sclerosis using wearable devices and smartphone technology. Such widely available devices can reveal a patient’s current condition, remotely, at previously unachievable levels of detail.
More information about clinical trials we conduct to determine whether new drugs are safe and effective when used to treat people is available on our Global website (see link). We ensure that regulatory agencies and ethics committees have approved the conduct of the clinical trial, and that the trial is conducted in accordance with applicable laws and regulatory requirements including ethical and good clinical practice guidelines.